Adjuvant chemotherapy extends survival in pancreatic cancer

Adjuvant chemotherapy appeared associated with a significant survival benefit among patients with pancreatic ductal adenocarcinoma who underwent multiagent neoadjuvant chemotherapy and resection, according to study results.Investigators observed the survival benefit regardless patients lymph node status or resection margins.Healio spoke with Marco Del Chiaro, MD, division chief of surgical oncology with University of Colorado’s department of surgery, and visiting researcher Toshitaka Sugawara, MD, PhD, about the findings and their potential implications.Read More

Generated by Feedzy